TISSUE REGENIX GROUP PLC — Board/Management Information 2021

Jan 5, 2021

National Storage Mechanism | Additional information

RNS Number : 5173K

Tissue Regenix Group PLC

05 January 2021

Tissue Regenix Group plc

Confirmation of Board appointments

Leeds, 5 January 2021 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group") the regenerative medical devices company, announces that, following the Group's announcement on 4 December 2020, Brian Phillips and Trevor Phillips have been appointed to the Board as independent Non-Executive Directors of Tissue Regenix.

Brian Phillips is now Chair of the Audit Committee and Trevor Phillips is Chair of the Remuneration Committee. 

For more Information:

Tissue Regenix Group plc Caitlin Pearson                                 Head of Communications	Tel: 0330 430 3052
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Alex Price	Tel:  0207 710 7600

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

Regulatory disclosures

Trevor Michael Phillips, 59, has been a director or partner of the following companies or partnerships during the past five years:

Current directorships/partnerships	Directorships/partnerships within the last 5 years
Prostratex Limited	Vectura Group Investments Limited
NEPeSMO Limited	hVIVO Limited
	hVIVO Services Limited
	Open Orphan plc
	Morvus Technology Limited
	Prep Biopharm Limited Imutex Limited
	Quadrant Drug Delivery Limited
	QDose Limited
	Quadrant Technologies Limited
	Quadrant Healthcare Limited
	Quadrant Holdings Cambridge Limited
	Quadrant Healthcare (UK) Limited
	Quadrant Trustee Limited
	Quadrant Bioresources Limited
	Protosome Limited
	Andaris Group Limited
	Andaris (DDS) Limited
	Microshot Limited
	Innovata Biomed Limited
	Innovata Limited
	Vectura Group Services Limited

Trevor holds no shares in Tissue Regenix plc and there are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

George Brian Phillips, 60, has been a director or partner of the following companies or partnerships during the past five years:

Current directorships/partnerships	Directorships/partnerships within the last 5 years
NAHL Group plc	Dig Space Limited
Muirfield Finance Limited	Tanygraig Limited
Muirfield Midco Limited	Preoday Limited
Muirfield Holdco Limited
Motocaddy Holdings Limited
Motocaddy Limited
Ethos Partners LLP
Imbiba Capital Limited
Imbiba (FP) LLP
Imbiba (GP) LLP
Imbiba Growth LLP
Purple Dragon (Holdings) Limited
Qikserve Limited
E&P Data Licensing Limited
The Jane Bubear Sport Foundation

Brian Phillips was a director of Valiant Sport Holdings Limited at the time it was placed into voluntary liquidation by members and creditors on 2 April 2013. The company was dissolved on 5 September 2014. There were no secured or preferential creditors. Unsecured creditors holding approximately £2.65m in aggregate received 0.7124p in pound.

Brian holds no shares in Tissue Regenix plc and there are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFLFFTLEISIIL